Coronary heart disease (CHD) is characterized by a high incidence rate and a substantial disease burden. Although conventional Western medicine can effectively manage cardiovascular risk factors and achieve coronary revascularization, it often fails to adequately address microcirculation disturbance, residual inflammatory risk, and the lack of holistic systemic regulation. In traditional Chinese medicine (TCM), CHD falls under the categories of “Xiongbi” (chest obstruction) and “Xintong” (cardiac pain), with “qi deficiency and blood stasis” identified as the core pathogenesis. This concept aligns closely with the modern pathological network of “vascular injury-inflammatory immune response-metabolic dysregulation”. Qishen Yiqi Dripping Pills (芪参益气滴丸, QSYQ), a Chinese patent medicine composed of Huangqi (Astragali Radix), Danshen (Salviae Miltiorrhizae Radix et Rhizoma), Sanqi (Notoginseng Radix et Rhizoma), and Jiangxiang (Dalbergiae Odoriferae Lignum), strictly adheres to the therapeutic principle of supplementing qi and activating blood, offering distinct advantages in multi-target systemic regulation. Centered on the theme of systemic regulation and precise intervention, this review first elucidates the scientific connotation of qi deficiency and blood stasis and maps its correlation with modern pathological networks. It then establishes a three-tiered mechanistic framework spanning “molecular events-signaling pathways-biological effects” to systematically decode the synergistic regulatory networks of QSYQ in anti-inflammation, anti-oxidation, anti-apoptosis, angiogenesis promotion, and energy metabolism optimization. Furthermore, a hierarchical clinical evidence evaluation system is constructed to summarize the therapeutic value of QSYQ in alleviating symptoms, improving cardiac function, enhancing long-term prognosis, and managing special patient populations. Future research should leverage multi-omics technologies and real-world evidence studies to further elucidate the underlying mechanisms of action. Additionally, high-quality evidence-based studies should be conducted to standardize evaluation criteria and optimize individualized medication regimens, ultimately promoting the standardized clinical application of QSYQ in the integrative traditional Chinese and Western medicine treatment of coronary heart disease.

coronary heart disease  /  Qishen Yiqi Dripping Pills  /  qi deficiency and blood stasis  /  mechanisms of action  /  clinical efficacy